  | Gennigens, C., Altintas, S., Baurain, J.-F., Denys, H., Henry, S., Vergote, I., & Van Gorp, T. (March 2024). Immunotherapy for advanced endometrial carcinoma: Time for a paradigm shift? Belgian Journal of Medical Oncology, 18 (2), 49-59.  Peer Reviewed verified by ORBi |
  | Motzer, R. J., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Alekseev, B., Rha, S. Y., Merchan, J., Goh, J. C., Lalani, A.-K. A., De Giorgi, U., Melichar, B., Hong, S.-H., Gurney, H., Méndez-Vidal, M. J., Kopyltsov, E., Tjulandin, S., Gordoa, T. A., ... Gennigens, C. (Other coll.). (2024). Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of Clinical Oncology, 2301569. doi:10.1200/JCO.23.01569 Peer Reviewed verified by ORBi |
 | Baccus, L., Dheur, A., Salmon, A., Delbecque, K., Goffin, F., De Cuypere, M., PLEYERS, C., Lovinfosse, P., Danthine, D., THILLE, A., Gonne, E., Gennigens, C., Kridelka, F., & Kakkos, A. (2024). 414 Potential association between quantified LVSI status and molecular profile in predicting nodal metastases for patient suffering early-stage endometrial cancer. International Journal of Gynecological Cancer, 34, 177-A178. Peer Reviewed verified by ORBi |
 | Martínez, A. G., Martin-Calvo, N., Meydanli, M. M., Khatib, G., Kaidarova, D., Ayhan, A., Borella, F., Sanchez-Salcedo, M., Sanci, M., Chaves, C. B. B. P., Elsersy, M. A. M., Bolatbekova, R., Vorias, G., Gil-Moreno, A., Perrone, A. M., Mishra, J., Zusterzeel, P., Theodoulidis, V., Aluloski, I., ... De Agustin, L. C. (2024). #819 Primary results of DAYDREAM study, a real-world multicentre study on the efficacy of adjuvant chemotherapy in high-grade uterine sarcomas. International Journal of Gynecological Cancer, 34, 573. Peer Reviewed verified by ORBi |
 | Grisham, R., Aghajanian, C., Nieuwenhuysen, E. V., Rodrigues, M., Ring, K., Santin, A., Colombo, N., Prendergast, E., Thaker, P., Moore, K., Salinas, E., Ray-Coquard, I., Chon, H. S., Rose, P., Oaknin, A., Clamp, A., Gandhi, M., Monk, B., Holloway, R., ... Banerjee, S. (2023). PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy. International Journal of Gynecological Cancer. doi:10.1136/ijgc-2023-igcs.4 Peer reviewed |
 | Morfouace, M., Oliveira, J., Penel, N., Peron, J., Pracht, M., Brasiuniene, B., Capela Marques, A., Gennigens, C., Greillier, L., Robert, M.-S., Klumpen, H. J., Peeters, R., Licitra, L. F. L., Girard, N., Gietema, J. A., de Herder, W., Kapiteijn, E., Idbaih, A., Ray-Coquard, I. L., & Blay, J.-Y. (October 2023). 132MO Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study. Annals of Oncology, 34, 233-S234. doi:10.1016/j.annonc.2023.09.2857 Peer Reviewed verified by ORBi |
 | DEMARTEAU, C., PLEYERS, C., HERMESSE, J., Gennigens, C., Kakkos, A., Gonne, E., Goffin, F., & Kridelka, F. (September 2023). #749 Optimizing brachytherapy applicators implantation in locally advanced cervical cancer with transrectal ultrasound guidance. International Journal of Gynecological Cancer, 33, 91-A92. doi:10.1136/ijgc-2023-esgo.183 Peer reviewed |
 | Banerjee, S. N., Ring, K. L., Niewenhuysen, E. V., Fabbro, M., Aghajanian, C., Oaknin, A., Colombo, N., Santin, A. D., Clamp, A. R., Moore, K. N., Rose, P. G., David M, O. M., Chon, H. S., Salinas, E. A., Prendergast, E. N., Lustgarten, S., Rodrigues, M., Gennigens, C., Monk, B. J., & Grisham, R. N. (September 2023). #523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). International Journal of Gynecological Cancer, 33, 20-A21. doi:10.1136/ijgc-2023-esgo.29 Peer reviewed |
 | Vergote, I., Van Nieuwenhuysen, E., O'Cearbhaill, R. E., Westermann, A., Lorusso, D., Ghamande, S., Collins, D. C., Banerjee, S., Mathews, C. A., Gennigens, C., Cibula, D., Tewari, K. S., Madsen, K., Köse, F., Jackson, A. L., Boere, I. A., Scambia, G., Randall, L. M., Sadozye, A., ... Monk, B. J. (2023). Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Journal of Clinical Oncology, 2300720. doi:10.1200/JCO.23.00720 Peer Reviewed verified by ORBi |
 | Vergote, I., Van Nieuwenhuysen, E., Casado, A., Laenen, A., Lorusso, D., Braicu, E. I., Guerra-Alia, E., Zola, P., Wimberger, P., Debruyne, P. R., Falcó, E., Ferrero, A., Muallem, M. Z., Kerger, J., García-Martinez, E., Pignata, S., Sehouli, J., Van Gorp, T., Gennigens, C., & Rubio, M. J. (July 2023). Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer. Gynecologic Oncology, 174, 80 - 88. doi:10.1016/j.ygyno.2023.04.028 Peer Reviewed verified by ORBi |
 | Mirza, M. R., Chase, D. M., Slomovitz, B. M., dePont Christensen, R., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L. M., Hanker, L. C., Stuckey, A., Boere, I., Gold, M. A., Auranen, A., Pothuri, B., Cibula, D., McCourt, C., Raspagliesi, F., ... Gennigens, C. (Other coll.). (08 June 2023). Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. New England Journal of Medicine, 388 (23), 2145 - 2158. doi:10.1056/NEJMoa2216334 Peer Reviewed verified by ORBi |
 | Banerjee, S. N., Ring, K. L., Van Nieuwenhuysen, E., Fabbro, M., Aghajanian, C., Oaknin, A., Colombo, N., Santin, A., Clamp, A. R., Moore, K. N., Rose, P. G., O'Malley, D. M., Chon, H. S., Salinas, E. A., Prendergast, E. N., Lustgarten, S., Rodrigues, M., Gennigens, C., Monk, B. J., & Grisham, R. N. (01 June 2023). Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). Journal of Clinical Oncology, 41 (16_suppl), 5515-5515. doi:10.1200/jco.2023.41.16_suppl.5515 Peer Reviewed verified by ORBi |
 | Verbiest, A., Baldewijns, M., Beuselinck, B., Debruyne, P., Gennigens, C., Pelgrims, G., Roumeguère, T., Seront, E., Sundahl, N., & Rottey, S. (June 2023). Update on the management of renal cell carcinoma: The BSMO expert panel recommendations. Belgian Journal of Medical Oncology, 17 (4), 118-127. Peer Reviewed verified by ORBi |
 | Boere, I., Vergote, I., Hanssen, R., Jalving, M., Gennigens, C., Ottevanger, P., van de Wouw, Y. J., Rijcken, C. J. F., Mathijssen, R. H. J., & Ledermann, J. (2023). CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer. International Journal of Gynecological Cancer, 2023-004308. doi:10.1136/ijgc-2023-004308 Peer Reviewed verified by ORBi |
 | Lucia, F., Bourbonne, V., PLEYERS, C., Dupré, P.-F., Miranda, O., Visvikis, D., Pradier, O., Abgral, R., Mervoyer, A., Classe, J.-M., Rousseau, C., Vos, W., HERMESSE, J., Gennigens, C., De Cuypere, M., Kridelka, F., Schick, U., Hatt, M., Hustinx, R., & Lovinfosse, P. (2023). Multicentric development and evaluation of 18F-FDG PET/CT and MRI radiomics models to predict para-aortic lymph node involvement in locally advanced cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging. doi:10.1007/s00259-023-06180-w Peer Reviewed verified by ORBi |
 | Streel, S.* , Salmon, A.* , DHEUR, A., Bours, V., LEROI, N., Habran, L., Delbecque, K., Goffin, F., PLEYERS, C., Kakkos, A., Gonne, E., Seidel, L., Kridelka, F.* , & Gennigens, C.*. (02 March 2023). Diagnostic Performance of Immunohistochemistry Compared to Molecular Techniques for Microsatellite Instability and p53 Mutation Detection in Endometrial Cancer. International Journal of Molecular Sciences, 24 (5), 4866. doi:10.3390/ijms24054866 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Gennigens, C., Denys, H., Altintas, S., Kerger, J., Baurain, J.-F., Bours, V., Henry, S., Van De Vijver, K., Lambrechts, D., & Vergote, I. (March 2023). Value of testing for homologous recombination repair deficiency in newly diagnosed advanced-stage epithelial ovarian cancer: Recommendations for Belgian physicians. Belgian Journal of Medical Oncology, 17 (2), 38-45. Peer Reviewed verified by ORBi |
 | DHEUR, A., Salmon, A., Streel, S., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., De Cuypere, M., Goffin, F., Lovinfosse, P., Kridelka, F., Kakkos, A., & Gennigens, C. (February 2023). p53 status : a strong negative prognostic factor in endometrial carcinoma [Poster presentation]. 25th BSMO Annual Meeting 2023, Hasselt, Belgium. Peer reviewed |
 | Salmon, A., Streel, S., DHEUR, A., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., De Cuypere, M., Goffin, F., Lovinfosse, P., Kakkos, A., Kridelka, F., & Gennigens, C. (February 2023). Agreement between immunohistochemistry and molecular techniques to assess microsatellite instability and p53 status in endometrial cancer [Poster presentation]. 25th BSMO Annual Meeting 2023, Hasselt, Belgium. Peer reviewed |
 | Kuchimanchi, M., Koliadi, A., Pothuri, B., Alskär, O., Krivak, T., Pishchyk, M., Hanze, E., Zajic, S., Segev, Y., Backes, F. J., Gennigens, C., Bouberhan, S., Buscema, J., Melhem, M., & Shahin, M. S. (2023). Exposure-Response Analysis of Dostarlimab in Combination with Platinum-Containing Chemotherapy in Primary Advanced or Recurrent Endometrial Cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial [Poster presentation]. American Conference on Pharmacometrics (ACoP), Maryland, United States. Peer reviewed |
 | Berton-Rigaud, D., Pautier, P., Lorusso, D., Gennigens, C., Gladieff, L., Kryzhanivska, A., Bowman, J., Tian, C., Cornfeld, M., & Van Gorp, T. (2023). Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H) [Poster presentation]. European Society for Medical Oncology Congress, Madrid, Spain. Peer reviewed |
 | Verdonck Beatove, E., Piette, C., Sautois, B., & Gennigens, C. (2023). Late metastatic relapse of an initially bifocal intracranial germ cell tumor with modestly elevated tumor markers: A case report [Poster presentation]. 25th BSMO Annual Meeting 2023, Hasselt, Belgium. Peer reviewed |
 | Gennigens, C., Enguita, A., & Feys, T. (2023). Highlights in gynaecological cancer. Belgian Journal of Medical Oncology, 17 (8), 298-303. Peer Reviewed verified by ORBi |
 | Gennigens, C. (2023). ADVANCED CERVICAL CANCER: CURRENT TREATMENTS AND FUTURE STRATEGIES. Belgian Journal of Medical Oncology. Peer Reviewed verified by ORBi |
 | HERMESSE, J., PLEYERS, C., Gennigens, C., De Cuypere, M., Lovinfosse, P., Seidel, L., Coucke, P., & Kridelka, F. (2023). Outcome analysis of HDR compared to PDR IGABT in locally advanced cervical cancer: a single-center cohort analysis. Strahlentherapie und Onkologie. doi:10.1007/s00066-022-01982-7 Peer Reviewed verified by ORBi |
 | Hennuy, C., Defrère, P., MAWEJA, S., Thiry, A., & Gennigens, C. (November 2022). Bilateral breast desmoid - type fibromatosis, case report and literature review. Gland Surgery, 11 (11), 1832-1841. doi:10.21037/gs-22-271 Peer Reviewed verified by ORBi |
 | Dheur, A., Bours, V., De Cuypere, M., Delbecque, K., Gennigens, C., Goffin, F., Gonne, E., HERMESSE, J., Kridelka, F., Lovinfosse, P., PLEYERS, C., Salmon, A., & Kakkos, A. (October 2022). 2022-RA-193-ESGO Cost-effectiveness of molecular profiling for endometrial neoplasia: a single institution experience [Poster presentation]. 23rd European Congress on Gynaecological Oncology. doi:10.1136/ijgc-2022-esgo.203 Peer reviewed |
 | Salmon, A., Dheur, A., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., De Cuypere, M., Goffin, F., Lovinfosse, P., Kridelka, F., Kakkos, A., & Gennigens, C. (October 2022). Endometrial cancer: lymphovascular space invasion is a negative prognostic factor [Poster presentation]. 23rd European Congress on Gynaecological Oncology. doi:10.1136/ijgc-2022-esgo.264 Peer reviewed |
 | DHEUR, A., Bours, V., De Cuypere, M., Delbecque, K., Gennigens, C., Goffin, F., Gonne, E., HERMESSE, J., Kakkos, A., Lovinfosse, P., PLEYERS, C., Salmon, A., & Kridelka, F. (29 September 2022). Defining prognostic risk groups amongst patients with endometrial cancer:respective role of 2009 figo stage and molecular profile [Poster presentation]. IGCS 2022, New York, United States. Peer reviewed |
 | Salmon, A., DHEUR, A., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., De Cuypere, M., Goffin, F., Lovinfosse, P., Kakkos, A., Kridelka, F., & Gennigens, C. (29 September 2022). Endometrial cancer: agreement between P53 immunohistochemistry and TP53 mutational analysis ? [Poster presentation]. IGCS 2022, New York, United States. Peer reviewed |
 | Gennigens, C., Jerusalem, G., LAPAILLE, L., De Cuypere, M., Streel, S., Kridelka, F., & Ray-Coquard, I. (09 September 2022). Recurrent or primary metastatic cervical cancer: current and future treatments. ESMO Open, 7 (5), 1-3. doi:10.1016/j.esmoop.2022.100579 Peer Reviewed verified by ORBi |
 | I. Vergote, H. Denys, S. Altintas, J. Kerger, J-F. Baurain, Bours, V., S. Henry, K. Van de Vijver, D. Lambrechts, & Gennigens, C. (2022). Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer:A Belgian expert opinion. Facts, Views and Vision in Obgyn, 14 (2), 111-120. Peer Reviewed verified by ORBi |
 | De Cuypere, M., PLEYERS, C., HERMESSE, J., Lovinfosse, P., Delbecque, K., Gonne, E., Kakkos, A., Goffin, F., Kridelka, F., & Gennigens, C. (2022). A comparison of survival and recurrence pattern of patients presenting locally advanced cervical cancer according to the histological subtype: a monocentric retrospective study [Poster presentation]. 23rd European Congress on Gynecological Oncology, Berlin, Germany. Peer reviewed |
 | Vergote, I., Van Nieuwenhuysen, E., De Waele, S., Vulsteke, C., Lamot, C., Van den Bulck, H., Claes, N., Graas, M.-P., Delbrock, G., Spoormans, I., Vuylsteke, P., Honhon, B., Verhoeven, D., De Maeseneer, D., Dirix, L., Mebis, J., Vroman, P., Denys, H., Martinez Mena, C., ... GENNIGENS, C. (2022). Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer : a study of the Belgian and Luxembourg Gynaecological Oncology Group. International Journal of Gynecological Cancer, 1-8. doi:10.1136/ijgc-2021-003190 Peer Reviewed verified by ORBi |
 | Lamarca, A., Morfouace, M., Tejpar, S., Oliveira, J., Capela, A., Penel, N., Gennigens, C., Brasiuniene, B., Peron, J., Stevovic, A., Blay, J.-Y., & Klümpen, H.-J. (2022). Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few. Annals of Oncology. doi:10.1016/j.annonc.2022.07.006 Peer Reviewed verified by ORBi |
 | Mettlen, C., Gennigens, C., & Kurth, W. (2022). L’image du mois. Descellement aseptique d’une méga-prothèse de genou. Revue Médicale de Liège, 77 (1), 5-7. Peer reviewed |
 | Gennigens, C., DHEUR, A., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., Seidel, L., Streel, S., De Cuypere, M., Goffin, F., Lovinfosse, P., Kakkos, A., Kridelka, F., & Salmon, A. (2022). 2022-RA-967-ESGO Endometrial cancer: agreement between microsatellite instability in immunohistochemistry and molecular analysis ? International Journal of Gynecological Cancer. doi:10.1136/ijgc-2022-ESGO.266 Peer Reviewed verified by ORBi |
 | Berton, D., Pautier, P., Lorusso, D., GENNIGENS, C., Gladieff, L., Kryzhanivska, A., Ranganathan, S., Tian, C., Bourayou, N., & Vergote, I. (10 November 2021). Retifanlimab (INCMGA00012) in Patients With Recurrent MSI-H or dMMR Endometrial Cancer: Results From the POD1UM-101 Study [Poster presentation]. Society for Immunotherapy of Cancer's 36th Annual Meeting, Wasthington, United States - District of Columbia. |
 | ONESTI, C. E., Schroeder, H., Rorive, A., Sautois, B., Lecocq, M., Goffin, M., Gonne, E., Collinge, A., Nicolaers, L., Wéra, O., Catot, A., Loly, C., Paulus, A., Sibille, A., Lousberg, L., Troisfontaine, F., Collignon, J., Gennigens, C., Frères, P., ... Jerusalem, G. (2021). Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study. Cancer Reports, 1571. doi:10.1002/cnr2.1571 Peer reviewed |
 | Vergote, I., Van Nieuwenhuysen, E., Casado, A., Laenen, A., Lorusso, D., Braicu, I., Guerra-Alia, E., Zola, P., Wimberger, P., Debruyne, P., Falco, E., Ferrero, A., Muallem, M., Kerger, J., Garcia Martinez, E., Pignata, S., Sehouli, J., Van Gorp, T., GENNIGENS, C., & Rubio Pérez, M. (12 October 2021). Randomised phase II BGOG/ENGOT-CX1 study of Paclitaxel-Carboplatin with or without Nintedanib in first-line recurrent or advanced cervical cancer [Paper presentation]. Int J Gynecol Cancer: first published as 10.1136/ijgc-2021-ESGO.16. |
 | Vergote, I. B., Monk, B. J., O'Cearbhaill, R. E., Westermann, A. M., Banerjee, S., Collins, D. C., Mirza, M. R., O'Malley, D., GENNIGENS, C., Pignata, S., Melichar, B., Sadozye, Forget, F., Tewari, K. S., Gort, E., Soumaoro, I., Mondrup Andreassen, C., Nicacio, L. V., Van Nieuwenhuysen, E., & Lorusso, D. (19 September 2021). Tisotumab Vedotin + Carboplatin in First-Line or + Pembrolizumab in Previously Treated Recurrent/Metastatic Cervical Cancer: Interim Results of ENGOT-Cx8/GOG-3024/innovaTV 205 [Poster presentation]. Mini oral session - Gynaecological cancers. |
 | Monk, B., Van Gorp, T., Lorusso, D., O'Cearbhaill, R., Westermann, A., Banerjee, S., Collins, D., Klat, J., Madsen, K., Baurain, J., Jackson, A., Boere, I., Pignata, S., Gort, E., Moroney, J., Soumaoro, I., Mondrup Andreassen, C., Nicacio, L., GENNIGENS, C., & Vergote, I. (30 August 2021). Tisotumab vedotin + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer: phase 1b/2 ENGOT-Cx8/GOG-3024/innovaTV 205 study dose-escalation results [Poster presentation]. 2021 IGCS Annual Global Meeting; August 30-September 2, 2021; virtual. Plenary 5. |
 | Coleman, R., Lorusso, D., GENNIGENS, C., Gonzalez-Martin, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., Redondo, A., Vindelov, S., Chen, M., Harris, J., Smith, M., Nicacio, L., Teng, M., Laenen, A., Rangwala, R., ... Vergote, I. (May 2021). Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology, 22 (5), 609-619. doi:10.1016/S1470-2045(21)00056-5 Peer Reviewed verified by ORBi |
 | Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., Kozlov, V., Alyasova, A., Hong, S.-H., Kapoor, A., Alonso Gordoa, T., Merchan, J. R., Winquist, E., Maroto, P., Goh, J. C., ... Gennigens, C. (Other coll.). (08 April 2021). Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 384 (14), 1289 - 1300. doi:10.1056/NEJMoa2035716 Peer Reviewed verified by ORBi |
 | LAPAILLE, L., DE CUYPERE, M., GOFFIN, F., KAKKOS, A., GONNE, E., HERMESSE, J., LOVINFOSSE, P., DELBECQUE, K., THILLE, A., Kridelka, F., & GENNIGENS, C. (2021). Cancer du col utérin localement avancé : approche multidisciplinaire. Revue Médicale de Liège, 76 (5-6), 507-514. Peer reviewed |
 | GENNIGENS, C., DE CUYPERE, M., HERMESSE, J., KRIDELKA, F., & JERUSALEM, G. (2021). Optimal treatment in locally advanced cervical cancer. Expert Review of Anticancer Therapy, 657-671. doi:10.1080/14737140.2021.1879646 Peer Reviewed verified by ORBi |
 | Durieux, R., Tchana-Sato, V., LAVIGNE, J.-P., Radermecker, M., MOONEN, M., SCAGNOL, I., GENNIGENS, C., & Defraigne, J.-O. (2021). Recurrent cardiac intimal sarcoma misdiagnosed as a myxoma or malignant transformation of a cardiac myxoma? Journal of Cardiac Surgery, 36 (1), 357-362. doi:10.1111/jocs.15200 Peer Reviewed verified by ORBi |
 | Vergote, I., Denys, H., De Grève, J., GENNIGENS, C., Van de Vijver, K., Kerger, J., Vuylsteke, P., & Baurain, J.-F. (2021). Standard of care in 2021 for patients with ovarian cancer in Belgium. Belgian Journal of Medical Oncology, 15 (6), 286-91. Peer Reviewed verified by ORBi |
 | Vergote, I., Concin, N., Mirza Raza, M., Andreassen Mondrup, C., Lorusso, D., GENNIGENS, C., Banerjee, S., O'Cearbhaill Eilish, R., Campos, S., Nicacio Viana, L., Eaton, L., O'Malley, D., Soumaoro, I., & Monk, B. (May 2020). Phase Ib/II trial of tisotumab vedotin+/- bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024) [Poster presentation]. ASCO, United States. |
 | Delafontaine, B., De Backer, C., Beuselinck, B., Debruyne, P., D'Hondt, L., GENNIGENS, C., Gil, T., Vulsteke, C., Martinez-Chanza, N., Verbiest, A., Strijbos, M., Van Lancker, G., Pelgrims, G., & Rottey, S. (March 2020). An update on the management of metastatic clear-cell renal cell carcinoma: the BSMO expert panel recommendations. Belgian Journal of Medical Oncology, 14 (2). Peer Reviewed verified by ORBi |
 | GENNIGENS, C., DE CUYPERE, M., HERMESSE, J., Barbeaux, A., Forget, F., KRIDELKA, F., & JERUSALEM, G. (February 2020). Impact of hemoglobin level and red blood cell transfusions in patients with locally advanced cervical cancer treated by chemoradiotherapy [Poster presentation]. 22nd Annual BSMO meeting, Gent, Belgium. |
 | Hong, D. S., Concin, N., Vergote, I., de Bono, J. S., Slomovitz, B. M., Drew, Y., Arkenau, H.-T., Machiels, J.-P., Spicer, J., Jones, R., Forster, M., Cornez, N., Gennigens, C., Johnson, M. L., Thistlethwaite, F. C., Rangwala, R. A., Ghatta, S., Windfeld, K., Harris, J. R., ... Coleman, R. L. (2020). Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. doi:10.1158/1078-0432.CCR-19-2962 Peer reviewed |
 | Gennigens, C., DE CUYPERE, M., SEIDEL, L., HERMESSE, J., Barbeaux, A., Forget, F., Albert, A., Jerusalem, G., & Kridelka, F. (2020). Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy. Cancer Medicine, 1-12. doi:10.1002/cam4.3465 Peer Reviewed verified by ORBi |
 | Verjans, J., KRIDELKA, F., DE CUYPERE, M., & GENNIGENS, C. (2020). Locally advanced cervical cancer : a descriptive analysis of 20 patients with a visceral recurrence. European Gynecology and Obstetrics, 2 (4), 255-261. Peer reviewed |
 | DE CUYPERE, M., LOVINFOSSE, P., GOFFIN, F., Gennigens, C., Rovira, R., Duch, J., Fastrez, M., Gebhart, G., Squifflet, J. L., Luyckx, M., Charaf, G., Crener, K., Buxant, F., Bucella, D., Jouret, M., Hustinx, R., & Kridelka, F. (2020). Added value of para-aortic surgical staging compared to (18)F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. doi:10.1016/j.ejso.2019.11.496 Peer reviewed |
 | ONESTI, C. E., SCHROEDER, H., RORIVE, A., SAUTOIS, B., LECOCQ, M., Goffin, M., GONNE, E., COLLINGE, A., NICOLAERS, L., WERA, O., Catot, A., LOLY, C., PAULUS, A., SIBILLE, A., LOUSBERG, L., Troisfontaine, F., COLLIGNON, J., GENNIGENS, C., FRERES, P., & JERUSALEM, G. (2020). How do oncological patients perceive the Covid-19 (SARS-CoV-2) pandemic ? Experience from CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain. |
 | LECOCQ, M., ONESTI, C. E., SCHROEDER, H., RORIVE, A., Goffin, M., GONNE, E., SAUTOIS, B., Catot, A., WERA, O., NICOLAERS, L., COLLINGE, A., Collignon, J., FRERES, P., POLUS, M., DUYSINX, B., VAILLANT, F., GENNIGENS, C., MARCHAL, N., PONCIN, A., & JERUSALEM, G. (2020). Risk of SARS-CoV-2 infection and outcome after infection : Experience from the day-care unit at CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain. |
 | DE CUYPERE, M.* , Lovinfosse, P.* , Gennigens, C., HERMESSE, J., Rovira, R., Duch, J., GOFFIN, F., Hustinx, R., & Kridelka, F. (2020). Tumor total lesion glycolysis and number of positive pelvic lymph nodes on pretreatment positron emission tomography/computed tomography (PET/CT) predict survival in patients with locally advanced cervical cancer. International Journal of Gynecological Cancer, 0, 1-8. doi:10.1136/ijgc-2020-001676 Peer reviewed* These authors have contributed equally to this work. |
 | Vergote, I., Denys, H., De Greve, J., Gennigens, C., Van De Vijver, K., Kerger, J., Vuylsteke, P., & Baurain, J. F. (2020). Treatment algorithm in patients with ovarian cancer. Facts, views & vision in ObGyn, 12 (3), 227-239. Peer reviewed |
 | DE CUYPERE, M., LOVINFOSSE, P., GOFFIN, F., SCHOENEN, S., Rovira Negre, R., Duch Renom, J., Fastrez, M., Gebhart, G., Luyckx, M., Squifflet, J.-L., Charaf, G., Krener, K., Buxant, F., Bucella, D., Jouret, M., & GENNIGENS, C. (03 November 2019). Added value of para-aortic surgical staging to 18F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer : an ONCO-GF study [Poster presentation]. ESGO 2019 Athens: 21st European Gynaecological Oncology Congress 2019, Athens, Greece. |
 | GENNIGENS, C., KRIDELKA, F., JERUSALEM, G., SEIDEL, L., GOFFIN, F., Barbeaux, A., Forget, F., KAKKOS, A., HERMESSE, J., GONNE, E., & DE CUYPERE, M. (2019). Lymphocytes count at diagnosis is a potential survival predictor in patients treated by chemoradiation in locally advanced cervical cancer [Poster presentation]. ESGO 2019 Athens: 21st European Gynaecological Oncology Congress 2019, Athens, Greece. |
 | GENNIGENS, C., & JERUSALEM, G. (2019). State of the art in the treatment of soft tissue sarcomas. Belgian Journal of Medical Oncology, 13 (6), 227-233. Peer Reviewed verified by ORBi |
 | Concin, N., Vergote, I., Lassen, U. N., Drew, Y., Machiels, J.-P., Arkenau, H.-T., Forster, M. D., Jones, R., Johnson, M. L., Slomovitz, B. M., Spicer, J. F., Cornez, N., GENNIGENS, C., Coleman, R. L., Windfeld, K., Ghatta, S., Rangwala, R. A., & Hong, D. S. (20 October 2018). A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer : updated analysis of full cervical expansion cohort [Poster presentation]. ESMO Congress 2018, Munich, Germany. |
 | Concin, N., Vergote, I., Dean, E., Lassen, U., Drew, Y., Machiels, J.-P., Nielsen, D., Arkenau, T., Forster, M., Jones, R., Slomovitz, B., Spicer, J., Johnsson, M., Cornez, N., GENNIGENS, C., Fulton, B., Rangwala, R., Coleman, R., & Hong, D. (November 2017). A phase IIa study of Tisotumab Vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer : updated safety and efficacy [Poster presentation]. ESGO European Gynaecological Oncology Congress 2017, Vienna, Austria. |
 | FRERES, P., GENNIGENS, C., Martin, D., & Jerusalem, G. (October 2017). Leptomeningeal carcinomatosis from solid tumours : a systematic review of the literature. Belgian Journal of Medical Oncology, 11, 259-264. Peer Reviewed verified by ORBi |
 | KREUTZ, J., Potorac, I., LUTTERI, L., GENNIGENS, C., MARTIN, D., Daly, A., BONNEVILLE, J.-F., TSHIBANDA, L., & BECKERS, A. (2017). Adipsic diabetes insipidus revealing a bifocal intracranial germinoma. Annales d'Endocrinologie. doi:10.1016/j.ando.2016.10.005 Peer Reviewed verified by ORBi |
 | Vergote, I., Concin, N., Dean, E., Lassen, U., De Bono, J., Drew, Y., Machiels, J., Nielsen, D., Arkenau, T., Forster, M., Jones, R., Slomovitz, B., Spicer, J., Johnson, M., Cornez, N., GENNIGENS, C., Fulton, B., Basse, L., Lisby, S., ... Hong, D. (2017). A phase IIA study of tisotumab vedotin (Humax - TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer. Annals of Oncology, 28 (suppl 5), 331. Peer Reviewed verified by ORBi |
 | GONNE, E., COLLIGNON, J., JERUSALEM, G., & GENNIGENS, C. (2016). Le carcinome de site primitif inconnu, une entité pas si rare. Revue Médicale de Liège, 71 (10), 449-454. Peer reviewed |
 | Crevecoeur, J., Jossa, V., GENNIGENS, C., Parmentier, J.-C., & Crevecoeur, A. (2015). Primary osteosarcoma of the breast : a case report. Clinical Case Reports. doi:10.1002/ccr3.450 Peer Reviewed verified by ORBi |
 | El Ali, Z., Van Brummelen, D., Wolter, P., Rottey, S., Altintas, S., Schallier, D., Debruyne, P., GENNIGENS, C., Van Aelst, F., Sideris, S., Gil, T., Sirtaine, N., D'Hondt, L., Luyten, D., Focan, C., Matus, G., Rasschaert, M., & Pelgrims, G. (February 2015). Management and systemic treatment of clear cell metastatic renal cell carcinoma: BSMO expert panel recommendations. Belgian Journal of Medical Oncology, 9 (1). Peer Reviewed verified by ORBi |
 | FRERES, P., GONNE, E., COLLIGNON, J., GIOT, J.-B., GENNIGENS, C., & JERUSALEM, G. (2015). Prise en charge de la neutropénie fébrile chez le patient cancéreux. Revue Médicale de Liège, 70 (4), 195-200. Peer reviewed |
 | LAKOSI, F., DE CUYPERE, M., NGUYEN, V. P., JANSEN, N., WARLIMONT, B., GULYBAN, A., GENNIGENS, C., SEIDEL, L., DELBECQUE, K., COUCKE, P., HERMESSE, J., & KRIDELKA, F. (2015). Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients : a mono-institutional experience. Acta Oncologica, 54 (9), 1558-1566. doi:10.3109/0284186X.2015.1062542 Peer Reviewed verified by ORBi |
 | VROONEN, L., Maiga, I., HAMOIR, E., LILET, H., GENNIGENS, C., & Beckers, A. (2014). Neurofibromatose et phéochromocytome métastatique. In Abstract book - Annales d'Endocrinologie : 31ème Congrès de la Société Françaose d'Endocrinologie, Lyon 5-8 novembre 2014 (pp. 474). |
 | Doupagne, A., DE CUYPERE, M., KRIDELKA, F., GOFFIN, F., DELBECQUE, K., GENNIGENS, C., LAKOSI, F., KAKKOS, A., & HERMESSE, J. (September 2014). Parametrial boost does not replace optimal BT treatment in 102 patients with locally advanced cervical cancer (LACC) [Paper presentation]. ESGO, Torino, Italy. |
 | BARTHELEMY, N., GENNIGENS, C., Scholtes, F., TSHIBANDA, L., OTTO, B., PIRET, P., MARTIN, D., JERUSALEM, G., & COUCKE, P. (2014). Le traitement multidisciplinaire du glioblastome. Revue Médicale de Liège, 69, 63-68. Peer reviewed |
 | Benoit, A., Jerusalem, G., & GENNIGENS, C. (2013). Le cas clinique du mois. Métastase musculaire en présence d'un cancer de l'ovaire. Revue Médicale de Liège, 68 (11), 557-61. Peer reviewed |
 | Vergote, I. B., Garcia, A., Micha, J., Pippitt, C., Bendell, J., Spitz, D., Reed, N., Dark, G., Fracasso, P. M., Ibrahim, E. N., Armenio, V. A., Duska, L., Poole, C., GENNIGENS, C., Dirix, L. Y., Leung, A. C. F., Zhao, C., Soufi-Mahjoubi, R., & Rustin, G. (2013). Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer. Journal of Clinical Oncology. doi:10.1200/JCO.2012.45.1278 Peer Reviewed verified by ORBi |
 | Sautois, B., & GENNIGENS, C. (2013). Actualites therapeutiques dans le traitement medical du cancer de la prostate resistant a la castration. Revue Médicale de Liège, 68 (2), 94-6. Peer reviewed |
 | Marchal, N., GENNIGENS, C., & JERUSALEM, G. (November 2012). Carcinomatose péritonéale d'origine indéterminée. Revue Médicale de Liège, 67 (11), 582-586. Peer reviewed |
 | Duerinck, J., Clement, P., Bouttens, F., Neyns, B., D'Hondt, L., GENNIGENS, C., Staelens, Y., Joosens, E., Van Fraeyenhove, F., & Rogiers, A. (September 2012). Bevacizumab for recurrent glioblastoma, early observations on patient outcome in the belgian medical need program. Neuro-Oncology, 14 (3), 51. Peer Reviewed verified by ORBi |
 | van der Graaf, W., Blay, J., Chawla, S., Kim, D., Bui-Nguyen, B., Casali, P., Schöffski, P., Aglietta, M., Staddon, A., Beppu, Y., Le Cesne, A., Gelderblom, H., Judson, I., Araki, N., Ouali, M., Marreaud, S., Hodge, R., Dewji, M., Coens, C., ... GENNIGENS, C. (19 May 2012). Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 379 (9829), 1879-1886. doi:10.1016/S0140-6736(12)60651-5 Peer Reviewed verified by ORBi |
 | GENNIGENS, C., & JERUSALEM, G. (2012). Pazopanib (Votrient) dans le traitement du cancer du rein et des sarcomes des tissus mous. Revue Médicale de Liège, 67 (7-8), 437-42. Peer reviewed |
 | Grünwald, V., Karakiewicz, P. I., Bavbek, S. E., Miller, K., Machiels, J.-P., Lee, S.-H., Larkin, J., Bono, P., Rha, S. Y., Castellano, D., Blank, C. U., Knox, J. J., Hawkins, R., Anak, O., Rosamilia, M., Booth, J., Pirotta, N., Bodrogi, I., & GENNIGENS, C. (2012). An international expanded-access programme of Everolimus : Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European Journal of Cancer, 48, 324-332. doi:10.1016/j.ejca.2011.06.054 Peer Reviewed verified by ORBi |
 | BARTHELEMY, N., JANSEN, N., GENNIGENS, C., DELGAUDINE, M., & COUCKE, P. (2012). y a-t-il une place pour la radiothérapie en fin de vie ? Revue Médicale de Liège, 67 (3), 128/132. Peer reviewed |
 | GENNIGENS, C., & Jerusalem, G. (2011). Trabectedine (ET-743/Yondelis) dans le traitement des sarcomes des tissus mous et du cancer de l'ovaire. Revue Médicale de Liège, 66 (7-8), 452-5. Peer reviewed |
 | Collignon, J., Gennigens, C., & Jerusalem, G. (July 2010). Assessment of Response to Therapy for Bone Metastases : Is it still a challenge in oncology ? PET Clinics, 5 (3), 311-326. doi:10.1016/j.cpet.2010.05.002 Peer Reviewed verified by ORBi |
Pellegrini, N., Nguyen Khac, M.-T., Racaru, T., Castronovo, C., Gennigens, C., Deprez, M., & Martin, D. (20 March 2010). Pan-spinal dissemination from a supratentorial primitive neuroectodermal tumor [Poster presentation]. Réunion annuelle de la Société Belge de Neurochirurgie, LIEGE, Belgium. |
 | Freres, P., Collignon, J., Gennigens, C., Scagnol, I., Rorive, A., Barbeaux, A., Coucke, P., & Jerusalem, G. (March 2010). Le cancer du sein "triple négatif". Revue Médicale de Liège, 65 (3), 120-126. Peer reviewed |
 | Gennigens, C., Sautois, B., & Jerusalem, G. (2010). Le medicament du mois. Everolimus (RAD001/Afinitor) dans le traitement du cancer du rein métastatique. Revue Médicale de Liège, 65 (4), 212-6. Peer reviewed |
 | Collignon, J., Gennigens, C., Rorive, A., Coucke, P., Lifrange, E., Maweja, S., Fillet, G., & Jerusalem, G. (May 2009). ANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques. Revue Médicale de Liège, 64 (5-6), 279-83. Peer reviewed |
 | Gennigens, C., Collignon, J., Jerusalem, G., Rorive, A., & Sautois, B. (2009). Anticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites. Revue Médicale de Liège, 64 (5-6), 264-7. Peer reviewed |
 | Gennigens, C., Kridelka, F., Jerusalem, G., & Sautois, B. (2009). Ovariumkanker : nieuwe cytotoxica en ontwikkeling van gerichte therapieën. Gunaïkeia. Koninklijke Belgische Vereniging voor Gynecologie en Verloskunde, 14 (6), 174-190. Peer reviewed |
 | PHAN BA, R., DEPRETER, M., GENNIGENS, C., LENELLE, L., PITANCE, F., MASSION, P., & CANIVET, J.-L. (2009). L'image du mois: Thrombus artériel pulmonaire proximal en échocardiographie. Revue Médicale de Liège, 64 (1), 4-5. Peer reviewed |
 | Mievis, C., Jansen, N., Schleich, F., Gennigens, C., Rorive, A., Jerusalem, G., Fillet, G., & Sautois, B. (2009). Le cas clinique du mois. Reaction de rappel d'irradiation induite par l'administration de cyclophosphamide. Revue Médicale de Liège, 64 (4), 179-81. Peer reviewed |
 | GONNE, E., Collignon, J., Kurth, W., Thiry, A., Henry, F., Jerusalem, G., & Gennigens, C. (2009). Angiosarcome sur lymphoedeme chronique: un cas de syndrome de Stewart-Treves. Revue Médicale de Liège, 64 (7-8), 409-13. Peer reviewed |
 | Christelbach, S., Vroonen, L., MAWEJA, S., Gennigens, C., & Beckers, A. (2008). A propos d'un cas de corticosurrénalome. Médecine Clinique Endocrinologie et Diabète, 34, 52-56. |
 | Paulus, A., Gennigens, C., Fillet, G., Loly, C., & Sautois, B. (September 2007). Traitement chimiothérapique actuel du cancer de l'ovaire. Revue Médicale de Liège, 62 (9), 539-47. Peer reviewed |
 | Gennigens, C., Sautois, B., Rorive, A., Fillet, G., & Jerusalem, G. (2007). Actualites therapeutiques en oncologie: l'essor des therapeutiques ciblees. Revue Médicale de Liège, 62 (5-6, May-Jun), 391-8. Peer reviewed |
 | Jerusalem, G., Rorive, A., Gennigens, C., Sautois, B., Mievis, C., & Fillet, G. (2007). Actualités thérapeutiques en oncologie sénologique: place actuelle et perspectives des traitements cibles. Revue Médicale de Liège, 62 Spec No, 2-5. Peer reviewed |
 | Gennigens, C., Menetrier-Caux, C., & Droz, J. P. (May 2006). Insulin-like growth factor (IGF) family and prostate cancer. Critical Reviews in Oncology/Hematology, 58 (2), 124-145. doi:10.1016/j.critrevonc.2005.10.003 Peer Reviewed verified by ORBi |
 | de Leval, L., Jardon-Jeghers, C., GENNIGENS, C., & BONIVER, J. (2006). Hodgkin's Lymphoma Presenting as a Bladder Tumour. Haematologica, 91 (3), 03. Peer Reviewed verified by ORBi |
 | Gennigens, C., Ray-Coquard, I., & Guastalla, J.-P. (May 2005). Cas clinique: Sarcomes utérins: À propos de 5 cas et revue de la littérature. Oncologie, 7 (4), 301 - 303. doi:10.1007/s10269-005-0228-7 Peer Reviewed verified by ORBi |
 | Gillain, S., Gennigens, C., Sautois, B., Polus, M., Bonnet, C., Fillet, G., & Jerusalem, G. (2004). Traitement du cancer du sein chez la personne âgée. Revue Médicale Suisse, 62, 1618-21. Peer Reviewed verified by ORBi |
 | Frere, P., Canivet, J.-L., Gennigens, C., Rebeix, J. P., Fillet, G., & Beguin, Y. (2000). Hyperammonemia after high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplantation, 26 (3), 343-5. doi:10.1038/sj.bmt.1702485 Peer Reviewed verified by ORBi |
